Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug
development remains challenging, with high costs, long pathways to clinical use and high …

Aliphatic polycarbonates have gained increased attention as biomaterials largely owing to
their biocompatibility and tunable degradation. Moreover, the ability to introduce functional …

Brain cancer, especially the most common type of glioblastoma, is highly invasive and
known as one of the most devastating and deadly neoplasms. Despite surgical and medical …

Protein-based therapeutics are an attractive alternative to established therapeutic
approaches and represent one of the fastest growing families of drugs. While many of these …

The blood–brain barrier (BBB), a unique structure in the central nervous system (CNS),
protects the brain from bloodborne pathogens by its excellent barrier properties …

Liposomes and polymersomes are colloidal vesicles that are self-assembled from lipids and
amphiphilic polymers, respectively. Because of their ability to encapsulate both hydrophilic …

Abstract Development of drug‐delivery systems that selectively target neoplastic cells has
been a major goal of nanomedicine. One major strategy for achieving this milestone is to …

Glioma is often referred to as one of the most dreadful central nervous system (CNS)-specific
tumors with rapidly-proliferating cancerous glial cells, accounting for nearly half of the brain …

The development of targeted nanomedicines for cancer therapy has been an utmost focus of
research across different fields including materials science, nanotechnology, biotechnology …

Cytosolic protein delivery offers opportunities to develop protein-based therapeutics
specifically modulate intracellular processes, especially those linked to 'undruggable'targets …